Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, Safety, and Tolerability of Two Eloralintide Solutions in Healthy Participants
NCT07701083Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of eloralintide in obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve and Maximum Concentration. Started Jul 2026; status: active, not recruiting.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07701083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07701083.